Gilead Sciences Inc.’s Trodelvy delayed progression of a common type of advanced breast cancer by 1.5 months in a study, a modest but statistically significant improvement that may help expand use of … https://www.bloomberg.com/news/articles/2022-06-04/gilead-breast-cancer-drug-delays-progression-by-1-5-months